General Question for the Week of September 23, 2024

Question:

What codes do we report for monoclonal antibody Beyfortus™?

Answer:

Effective October 6, 2023, two new codes (96380 and 96381) were introduced for reporting of monoclonal antibody Beyfortus™ (nirsevimab-alip) for RSV immunization. This revises earlier guidance that instructed to report injection of nirsevimab with the 96372. Do not report administration of SYNAGIS® (palivizumab) with 96380 or 96381.

This question was answered in our Coding Essentials for Infusion & Injection Therapy Services. For more hot topics relating to infusion services, please visit our store or call us at 1.800.252.1578, ext. 2.

TAGS: Compliance, Infusion & Injections, Medicare

CPT® copyright 2023 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.

Looking for an answer?

Compliance Question Archive

Sign Up for Compliance Question of the Week